Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INO-1800 + INO-9112
- Development stage
- Unknown
- Lead developer
- Inovio Pharmaceuticals
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
INO-1800 + INO-9112 is an investigational DNA immunotherapy combination developed by Inovio Pharmaceuticals for the treatment of chronic hepatitis B virus (HBV) infection. The regimen consists of two DNA plasmids: INO-1800, which encodes the Hepatitis B surface antigen (HBsAg) and Hepatitis B core antigen (HBcAg), and INO-9112, which encodes human interleukin-12 (IL-12) to act as an immune activator. Delivered via intramuscular injection followed by electroporation using the CELLECTRA device, the therapy is designed to generate a robust, virus-specific T-cell response, particularly CD8+ killer T cells, to clear chronically infected liver cells. The combination was evaluated in Phase I clinical trials in patients already receiving nucleos(t)ide analogue treatment. Although Roche initially partnered with Inovio to develop the program (designating INO-1800 as RG7795), the collaboration was discontinued in 2016, and all rights were returned to Inovio.
- Other names
- RG7795 + INO-9112
02
Targets
HBsAg (Hepatitis B surface antigen)HBc (Hepatitis B virus core protein)IL12 (Interleukin-12)
Beyond the preview
Go deeper on INO-1800 + INO-9112.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INO-1800 + INO-9112.